



| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | Complete if Known | | |
|--|-----------------------|--|-----------------------------------|---|--|--|
| | | | | Application Number | 10/685,267 | |
| | | | | Filing Date | October 14, 2003 | |
| Sheet | 1 | of | 1 | First Name Inventor | Ding, et al. | |
| Attorney Docket Number 20861 US4 | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | |
| Examiner Initials' | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited document MM-DD-YYYY | |
| | | Number | Kind Code ² (if known) | | | |
| | A | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | |
| Examiner Initials' | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Office ³ | Number | Kind Code ⁴ (if known) | | |
| ANL | B1 | WO99/21845 | Agouron Pharmaceuticals Inc. | | | 05/06/1999 |
| | B2 | WO00/75120 | Agouron Pharmaceuticals Inc. | | | 12/14/2000 |
| | B3 | WO97/16447 | Mitotix Inc. | | | 05/09/1997 |
| | B4 | WO99/43675 | Hoechst Marion Roussel Inc. | | | 09/02/1999 |
| | B5 | WO99/43676 | Hoechst Marion Roussel Inc. | | | 09/02/1999 |
| | B6 | WO98/33798 | Warner Lambert Co. | | | 08/06/1998 |
| | B7 | WO99/09030 | Warner Lambert Co. | | | 02/25/1999 |
| | B8 | WO00/39101 | Astrazeneca Ltd. | | | 07/06/2000 |
| | B9 | WO00/12485 | Zeneca Ltd. | | | 03/09/2000 |
| | B10 | WO99/24416 | Bristol-Myers Squibb Co. | | | 03/09/1999 |
| | B11 | WO99/21845 | Agouron Pharmaceuticals Inc. | | | 05/06/1999 |
| | B12 | WO 00/26202 | Pharmacia & UpJohn S.P.A. | | | 05/11/2000 |
| | B13 | WO 01/56567 | Novo Nordisk A/S | | | 08/09/2001 |
| | B14 | WO 01/60816 | Amgen Inc. | | | 08/23/2001 |
| | B15 | WO 01/79198 | Agouron Pharmaceuticals, Inc. | | | 12/25/2001 |
| ANL | B16 | WO 02/12250 | Agouron Pharmaceuticals, Inc. | | | 02/14/2002 |
| NON PATENT LITERATURE DOCUMENTS | | | | | | |
| ANL | C1 | Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vol. 92 pgs. 376-387 | | | | |
| | C2 | Chong, Wesley, K. M., Presentation at Gordon Conference on Medicinal Chemistry, Colby Sawyer College, New London, NH "Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August 2, 1999 (Copy of Conference Handout Enclosed) | | | | |
| | C3 | Fischer et al., Expert Opin. Investig. Drugs 12(6) pgs. 955-970 (2003) | | | | |
| ANL | C4 | Grant et al., Drug Resistance Vol. 6, pgs. 15-26 (2003) | | | | |
| Examiner Signature | | Date Considered | A. (Signature) 4/29/05 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

137761